Survival with ecthyma gangrenosum, a previously fatal complication of burns.
D000617:Aminoglycosides / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002056:Burns / Q000150:complications*; D002228:Carbenicillin / Q000627:therapeutic use; D002675:Child, Preschool; D003091:Colistin / Q000627:therapeutic use; D004473:Ecthyma / Q000188:drug therapy / Q000209:etiology* / Q000382:microbiology; D005260:Female; D005500:Follow-Up Studies; D005734:Gangrene / Q000188:drug therapy / Q000209:etiology* / Q000382:microbiology; D006801:Humans; D007223:Infant; D008297:Male; D010403:Penicillin Resistance; D011379:Prognosis; D011552:Pseudomonas Infections / Q000150:complications*; D012703:Serotyping; D012877:Skin Manifestations; D013411:Sulfadiazine / Q000627:therapeutic use; D014946:Wound Infection / Q000188:drug therapy / Q000382:microbiology; D005719:gamma-Globulins / Q000627:therapeutic use
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D005719:gamma-Globulins; D013411:Sulfadiazine; D002228:Carbenicillin; D003091:Colistin